UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, no par value CLVT New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _______ Commission Fi ...

Clarivate Reports Second Quarter 2024 Results — Reaffirms 2024 Outlook — London, UK -- August 6, 2024 Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights • Revenues of $650.3 million decreased 2.8% • Organic revenues decreased 0.6%, as an increase in subscription revenues of 0.7% was offset by a decrease in reoccurring revenues of 0.7% a ...

Leadership Transition - Clarivate Plc announced the appointment of Matti Shem Tov as the new CEO, effective August 9, 2024, succeeding Jonathan Gear, who will transition to a non-executive role until November 1, 2024 [1][2] - The Board and Jonathan Gear mutually agreed that new leadership is necessary for the next phase of Clarivate's value creation journey [2] Contributions and Achievements - Under Jonathan Gear's leadership, Clarivate restructured into three end-market segments, enhancing product innovation investments and customer commitment [2] - The restructuring has strengthened the company's balance sheet and positioned Clarivate to deliver tailored solutions globally [2] New CEO's Background - Matti Shem Tov has over 30 years of global leadership experience in software, data, and analytics, with a focus on driving innovation and growth [4] - He previously served as CEO of ProQuest and has held leadership roles in various companies, including Ex Libris and Surecomp [4] Future Outlook - Matti Shem Tov expressed his commitment to accelerating growth, increasing product innovation, and driving value creation for stakeholders [2][4] - The Board is confident that Shem Tov's expertise will help launch Clarivate into a new phase of accelerated organic growth [2]

— Reaffirms 2024 Outlook — LONDON, Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenues of $650.3 million decreased 2.8% Organic revenues decreased 0.6%, as an increase in subscription revenues of 0.7% was offset by a decrease in re-occurring revenues of 0.7% and transactional and other revenues of 4. ...

Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages The new platform features an upgraded technology stack and enhanced functionality while retaining its core capabilities. These improvements include an 80% reduction in loading times for targets, drugs, drug combinations and adverse events. The platform now offers faster search capabilities, a clearer visual design, full-screen visualization and additional analytic tools. OFF-X empowers users to monit ...

LONDON, July 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Richard Roedel will retire from the Board of Directors (the "Board") for health reasons, effective December 31, 2024. The Board expects Valeria Alberola, a member of the Board since May 2021, and a member of its Audit and Finance Committees, to succeed Mr. Roedel as Chair of the Audit Committee. Ms. Alberola brings over 25 years of global experience in corporate fi ...

Board Changes - Richard Roedel will retire from the Board of Directors for health reasons, effective December 31, 2024 [1] - Valeria Alberola, a Board member since May 2021, is expected to succeed Mr Roedel as Chair of the Audit Committee [1] - Andy Snyder, Board Chair, expressed gratitude for Mr Roedel's leadership and dedication since 2020 and confidence in Ms Alberola's ability to lead the Audit Committee [2] Valeria Alberola's Background - Ms Alberola brings over 25 years of global experience in corporate finance, investment banking, sustainable investments, operations, and strategic management consulting [2] - She served as CEO of Zoma Holdings, LLC from January 2019 to March 2024, following her tenure as COO from 2017 to December 2018 [2] - Previously, she was CFO of Bridge Education Group, Inc and a partner at Q Advisors LLC, advising on M&A and debt and equity financings for technology and telecommunications clients [2] - Ms Alberola holds a B S in Economics and Business Administration from Pontificia Universidad Católica de Chile and an M B A from Kellogg School of Management at Northwestern University, where she was a Fulbright scholar [2] Company Overview - Clarivate Plc is a leading global provider of transformative intelligence, offering enriched data, insights & analytics, workflow solutions, and expert services in Academia & Government, Intellectual Property, and Life Sciences & Healthcare [4]

Clarivate Plc (CLVT) recently partnered with OhioLINK and SearchOhio to integrate their INN-Reach platforms. Together, these three entities will develop a unified library solution for Ohio. The unification of OhioLINK and SearchOhio's resource platforms will enrich the database, giving the users extended choices. This partnership with OhioLINK and SearchOhio will help CLVT expand its market presence in the academic space. Clarivate provides its technology solutions to academia, government, intellectual prop ...

Core Insights - Clarivate Plc has acquired Rowan TELS Corp., enhancing its capabilities in patent management and prosecution through the integration of Rowan Patents, a solution designed for patent practitioners [1][5] Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, and workflow solutions across various sectors, including Intellectual Property [8] - Rowan TELS provides software solutions that incorporate automation and AI to address legal challenges faced by corporations and law firms [3] Strategic Goals - The acquisition aims to simplify and optimize intellectual property (IP) management, empowering organizations to protect and leverage their IP assets in a competitive market [2] - Clarivate plans to create an integrated end-to-end workspace for patent practitioners, combining AI and intelligent automation tools to support critical attorney tasks [2][4] Product Features - Rowan Patents offers an integrated environment for patent drafting, including claims, specifications, drawings, and biological sequences, ensuring consistency and efficiency [3][8] - The acquisition will extend Clarivate's workflow automation solutions, enhancing its existing IP management and intelligence capabilities [4][7] Market Positioning - Clarivate is positioned to provide automation and responsible AI-enabled solutions to patent practitioners, facilitating the efficient delivery of high-quality patent applications [4][5] - The company has been expanding its software support across the IP lifecycle, with recent enhancements to its patent maintenance and IP management software [7]

Core Insights - BioWorld, published by Clarivate Plc, has won nine 2024 APEX Awards for Publication Excellence, highlighting its commitment to journalistic excellence and data-driven analysis [1][2][3] Awards and Recognition - The APEX Awards, now in their 36th year, recognize outstanding work in professional communications, with over 1,100 entries this year, making BioWorld's nine wins particularly significant [2] - BioWorld has been recognized in various categories, including Grand Award in Writing and Awards for Publication Excellence in multiple writing categories [11][18] Notable Publications - A Grand Award was given for the writing category to Nuala Moran for an article on advancements in spinal cord injury treatments, showcasing BioWorld's focus on impactful medical innovations [4] - An award for writing the entire issue was given to a team for a June 2023 issue that included significant industry news, such as a series A financing for a gene therapy company and phase III data from a major oncology conference [5] - A series on radiopharmaceuticals was recognized for exploring new treatment modalities in oncology, indicating BioWorld's depth in covering emerging medical technologies [6] Industry Trends - The biopharma sector has seen a notable increase in deal values, with a nearly 6% uptick in overall deal value and an 80% increase in M&A values compared to the previous year, reflecting a transformative shift in the industry landscape [18] - The Asia-Pacific biotech ecosystems are experiencing a resurgence post-COVID-19, with countries like Singapore, China, and Japan attracting international collaborations to enhance their biotech capabilities [19]